On behalf of Illumina Cambridge Ltd.

By: Kerry S. Taylor

Michael L. Fuller

Nathanael R. Luman

KNOBBE, MARTENS, OLSON & BEAR, LLP

2040 Main Street, 14th Floor

Irvine, CA 92614 Tel.: 858-707-4000

Email: BoxIllumina2@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
COMPLETE GENOMICS, INC.
Petitioner
V.
ILLUMINA CAMBRIDGE LTD.
Patent Owner
IPR2017-02174 Patent 7,566,537

PRELIMINARY RESPONSE OF PATENT OWNER ILLUMINA CAMBRIDGE LTD.

Columbia Ex. 2010 Illumina, Inc. v. The Trustees of Columbia University



TABLE OF CONTENTS

I.	INT	RODUCTION	1	
II.	ANI	UMINA'S CLAIMED INVENTION INCLUDES A NOVEL D NONOBVIOUS 3'-OH PROTECTING GROUP FOR DNA QUENCING		
III.	PRE	BOARD, FEDERAL CIRCUIT, AND DISTRICT COURT VIOUSLY UPHELD PATENTABILITY OF THE ALLENGED CLAIMS	12	
	A.	The Board previously upheld the same claims in IPR2013-00517	12	
	B.	The Federal Circuit affirmed the Board's Decision from IPR2013-00517	14	
	C.	The Northern District of California upheld the same claims from the same patent	14	
IV.		'S SECOND FOLLOW-ON PETITION SHOULD BE NIED UNDER 35 U.S.C. § 314(A)	15	
	A.	Factor 1: Whether the same petitioner previously filed a petition directed to the same claims of the same patent	19	
	В.	Factor 2: Whether at the time of filing of the first petition the petitioner knew of the prior art asserted in the second petition or should have known of it	21	
	C.	Factor 3: Whether the petitioner already received the patent owner's preliminary response to the first petition or received the Board's decision on whether to institute review in the		
		first petition	22	



TABLE OF CONTENTS (cont'd)

	D.	Factor 4: The length of time that elapsed between the time the petitioner learned of the prior art asserted in the second petition and the filing of the second petition	23
	E.	Factor 5: Whether the petitioner provides adequate explanation for the time elapsed between the filings of multiple petitions directed to the same claims of the same patent	24
	F.	Factor 6: The finite resources of the Board	25
	G.	Factor 7: The requirement under 35 U.S.C. § 316(a)(11) to issue a final determination not later than 1 year after the date on which the Director notices institution of review	25
V.	THE	PERSON OF ORDINARY SKILL	26
VI.	NEW	CLAIM CONSTRUCTION IS UNNECESSARY	27
VII.	THE	LAW OF NONOBVIOUSNESS	27
VIII.		RE WAS NO MOTIVATION TO COMBINE DOWER I ZAVGORODNY AND CHURCH	27
	A.	Introduction to Dower, Zavgorodny, and Church	28
	B.	BGI Primary Issue 1: A POSITA would not have expected a 3'-O-azidomethyl group to be efficiently and accurately incorporated by a polymerase	29
		1. There was no motivation to use an azidomethyl group in Dower's sequencing methods because there was no expectation of efficient and accurate polymerase incorporation	30



TABLE OF CONTENTS (cont'd)

		2.	BGI has not shown there was a reasonable expectation of success in arriving at the claimed "incorporation"	39
	C.	BGI Primary Issue 2: A POSITA would not have expected azidomethyl removal conditions to be "mild" for Dower's SBS method		
		1.	Phosphine deblocking conditions produce amines	41
		2.	Pyridine was a known DNA denaturant	44
		3.	Young's cleavage conditions were not mild	44
	D.	azido	Primary Issue 3: A POSITA would not have expected omethyl to be cleaved with appropriate efficiency for	45
	E.	electr	fails to address Illumina's evidence that the rophilic 3'-O-azidomethyl group would not be patible with nucleophiles within the polymerase active	47
IX.			THYL WAS NOT A SIMPLE SUBSTITUTION INTO SBS METHOD	50
X.			ION IS LACKING FROM BGI'S PETITION THAT IT IN ILLUMINA'S PETITIONS	52
XI.	THE	DEPE	NDENT CLAIMS ARE NONOBVIOUS	54
XII.		_	MS ARE NOT OBVIOUS IN LIGHT OF RY CONSIDERATIONS OF NONOBVIOUSNESS	55
	A.		was aware of Illumina's evidence of non-obviousness, ailed to address the evidence	55



TABLE OF CONTENTS (cont'd)

	В.	BGI avoids addressing Illumina's previously-presented unexpected results by using an unsupported and incorrect legal theory	56
	C.	BGI avoids addressing Illumina's previously-presented evidence of long-felt, unmet need	57
	D.	BGI incorrectly argues that since there is no evidence of a competing commercial product, there can be no evidence of copying	59
VIII	CON	CLUSION	60



DOCKET A L A R M

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

